Literature DB >> 21060149

Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis.

Isabel Ben-Batalla1, Samuel Seoane, Tomas Garcia-Caballero, Rosalia Gallego, Manuel Macia, Luis O Gonzalez, Francisco Vizoso, Roman Perez-Fernandez.   

Abstract

The Pit-1 transcription factor (also know as POU1F1) plays a critical role in cell differentiation during organogenesis of the anterior pituitary in mammals and is a transcriptional activator for pituitary gene transcription. Increased expression of Pit-1 has been reported in human tumorigenic breast cells. Here, we found that Pit-1 overexpression or knockdown in human breast cancer cell lines induced profound phenotypic changes in the expression of proteins involved in cell proliferation, apoptosis, and invasion. Some of these protumorigenic effects of Pit-1 were mediated by upregulation of Snai1, an inductor of the epithelial-mesenchymal transition. In immunodeficient mice, Pit-1 overexpression induced tumoral growth and promoted metastasis in lung. In patients with invasive ductal carcinoma of the breast and node-positive tumor, high expression of Pit-1 was significantly correlated with Snai1 positivity. Notably, in these patients elevated expression of Pit-1 was significantly and independently associated with the occurrence of distant metastasis. These findings suggest that Pit-1 could help to make a more accurate prognosis in patients with node-positive breast cancer and may represent a new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060149      PMCID: PMC2993584          DOI: 10.1172/JCI42015

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 3.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

4.  The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells.

Authors:  V Budhram-Mahadeo; D Ndisang; T Ward; B L Weber; D S Latchman
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

Review 5.  POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease.

Authors:  B Andersen; M G Rosenfeld
Journal:  Endocr Rev       Date:  2001-02       Impact factor: 19.871

Review 6.  Prognostic significance of apoptosis regulators in breast cancer.

Authors:  S Krajewski; M Krajewska; B C Turner; C Pratt; B Howard; J M Zapata; V Frenkel; S Robertson; Y Ionov; H Yamamoto; M Perucho; S Takayama; J C Reed
Journal:  Endocr Relat Cancer       Date:  1999-03       Impact factor: 5.678

7.  Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line.

Authors:  C Gil-Puig; M Blanco; T García-Caballero; C Segura; R Pérez-Fernández
Journal:  J Endocrinol       Date:  2002-04       Impact factor: 4.286

Review 8.  The role of prolactin and growth hormone in breast cancer.

Authors:  H Wennbo; J Törnell
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

9.  Correlation of Snail expression with histological grade and lymph node status in breast carcinomas.

Authors:  Maria J Blanco; Gema Moreno-Bueno; David Sarrio; Annamaria Locascio; Amparo Cano; José Palacios; M Angela Nieto
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

10.  Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.

Authors:  Erica L McCoy; Ritsuko Iwanaga; Paul Jedlicka; Nee-Shamo Abbey; Lewis A Chodosh; Karen A Heichman; Alana L Welm; Heide L Ford
Journal:  J Clin Invest       Date:  2009-08-24       Impact factor: 14.808

View more
  20 in total

1.  Research resource: A genome-wide study identifies potential new target genes for POU1F1.

Authors:  Jean-Paul Herman; Nicolas Jullien; Séverine Guillen; Alain Enjalbert; Isabelle Pellegrini; Jean-Louis Franc
Journal:  Mol Endocrinol       Date:  2012-05-25

2.  Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese.

Authors:  Shusuke Akamatsu; Ryo Takata; Christopher A Haiman; Atsushi Takahashi; Takahiro Inoue; Michiaki Kubo; Mutsuo Furihata; Naoyuki Kamatani; Johji Inazawa; Gary K Chen; Loïc Le Marchand; Laurence N Kolonel; Takahiko Katoh; Yuko Yamano; Minoru Yamakado; Hiroyuki Takahashi; Hiroki Yamada; Shin Egawa; Tomoaki Fujioka; Brian E Henderson; Tomonori Habuchi; Osamu Ogawa; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Nat Genet       Date:  2012-02-26       Impact factor: 38.330

3.  A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer.

Authors:  Noemí Eiró; Belen Fernandez-Garcia; Julio Vázquez; José M Del Casar; Luis O González; Francisco J Vizoso
Journal:  Oncoimmunology       Date:  2015-01-29       Impact factor: 8.110

4.  Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.

Authors:  Anxo Martinez-Ordoñez; Samuel Seoane; Pablo Cabezas; Noemi Eiro; Juan Sendon-Lago; Manuel Macia; Tomas Garcia-Caballero; Luis O Gonzalez; Laura Sanchez; Francisco Vizoso; Roman Perez-Fernandez
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

5.  Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Authors:  J S Waizenegger; I Ben-Batalla; N Weinhold; T Meissner; M Wroblewski; M Janning; K Riecken; M Binder; D Atanackovic; H Taipaleenmaeki; D Schewe; S Sawall; V Gensch; M Cubas-Cordova; A Seckinger; W Fiedler; E Hesse; N Kröger; B Fehse; D Hose; B Klein; M S Raab; K Pantel; C Bokemeyer; S Loges
Journal:  Leukemia       Date:  2014-08-08       Impact factor: 11.528

6.  Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13.

Authors:  Juan Sendon-Lago; Samuel Seoane; Noemi Eiro; Maria A Bermudez; Manuel Macia; Tomas Garcia-Caballero; Francisco J Vizoso; Roman Perez-Fernandez
Journal:  Breast Cancer Res       Date:  2014-12-20       Impact factor: 6.466

7.  Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment.

Authors:  Samuel Seoane; Efigenia Arias; Rita Sigueiro; Juan Sendon-Lago; Anxo Martinez-Ordoñez; Esteban Castelao; Noemí Eiró; Tomás Garcia-Caballero; Manuel Macia; Rafael Lopez-Lopez; Miguel Maestro; Francisco Vizoso; Antonio Mouriño; Roman Perez-Fernandez
Journal:  Oncotarget       Date:  2015-06-10

8.  POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).

Authors:  Susana Lisboa; Nuno Cerveira; Susana Bizarro; Cecília Correia; Joana Vieira; Lurdes Torres; José M Mariz; Manuel R Teixeira
Journal:  Mol Cancer       Date:  2013-01-18       Impact factor: 27.401

9.  Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells.

Authors:  A El-Gazzar; X Cai; R S Reeves; Z Dai; A Caballero-Benitez; D L McDonald; J Vazquez; T A Gooley; G E Sale; T Spies; V Groh
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

10.  26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines.

Authors:  Samuel Seoane; Maria A Bermudez; Juan Sendon-Lago; Anxo Martinez-Ordoñez; Soraya Abdul-Hadi; Miguel Maestro; Antonio Mouriño; Roman Perez-Fernandez
Journal:  Cancers (Basel)       Date:  2013-12-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.